BioSpace News Archive

Drug Development

Akeso Doses First Patient In The Phase III Trial Of Ivonescimab Combined With Chemotherapy In EGFR-TKI Resistant EGFR Mutation Advanced Non-squamous Non-small Cell Lung Cancer

Akeso, Inc. announces that the first patient was dosed in a Phase III registrational clinical trial of the Company’s novel immuno-oncology drug, Ivonescimab, combined with chemotherapy versus placebo combined with chemotherapy for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer with EGFR mutation failed after EGFR-TKI treatment.

January 30, 2022
·
3 min read
Drug Development

Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom on Monday, January 31st

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases, plans to announce topline results from the Phase 3 MAESTRO-NAFLD-1 study of resmetirom on Monday, January 31st, 2022.

January 30, 2022
·
1 min read
Business

Appendix 4C Quarterly Activity ReportMesoblast Prepares for Resubmission of Biologics License Application

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, provided an operational and financial activity report for the second quarter ended December 31, 2021.

January 30, 2022
·
8 min read
Drug Development

Akeso’s Ligufalimab And Ivonescimab Obtained Approval To Initiate A Phase II Trial

Akeso, Inc. announces that the Ligufalimab and Ivonescimab has obtained approval from the Center for Drug Evaluation of the National Medical Products Administration of the People’s Republic of China to initiate a phase II clinical trial with chemotherapy as first-line therapy for unresectable locally advanced or metastatic triplenegative breast cancer.

January 30, 2022
·
2 min read